Cybin Inc
CYBN
Get informed when a big investor buys or sells
+ FollowMarket Cap$200.42M
Close$
$0.52
93.7% downside
Current Fair Value
93.7% downsideOvervalued by 93.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $200.42 Million |
|---|---|
| Enterprise Value | $34.33 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.61 |
| Beta | 0.79 |
| Outstanding Shares | 24,205,871 |
Return
| Return on Equity | -70.01% |
|---|---|
| Return on Assets | -65.27% |
| Return on Invested Capital | -68.27% |
Valuation & Multiples
| P/E Ratio | -2.84 |
|---|---|
| PEG | -3.18 |
| Price to Sales | - |
| Price to Book Ratio | 0.92 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.21 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
February 9, 2026
EPS Estimate
$-0.53
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1031▲ 0.13% |
|---|---|
| Total Calls | 613,200▲ 29.50% |
| Total Puts | 63,200▲ 31.12% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 124.29%▲ 86.18% |
|---|---|
| Total Invested | $246.55M▲ 353.94% |
| Investors Holding | 84▲ 6.00% |
ESG Score
No data
About Cybin Inc
100 employees
CEO: Michael I. Halstead Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer fr...